1. Introduction {#sec1}
===============

Ki67 is universally expressed in proliferating cells and has become a nuclear proliferation marker of malignant tumors \[[@bib1],[@bib2]\]. Several studies have demonstrated the prognostic value of the Ki67 label index (LI) for breast cancer patients \[[@bib3], [@bib4], [@bib5], [@bib6]\]. Potential uses of Ki67 LI include the prediction of the relative responsiveness or resistance to chemotherapy, estimation of the residual risk in patients on standard therapy and as a dynamic biomarker of treatment efficacy in samples taken before, during, and after neoadjuvant therapy, particularly neoadjuvant endocrine therapy \[[@bib7]\]. Currently, the assessment of Ki67 using immunohistochemical (IHC) staining in breast cancer subtypes has become widespread.

However, the assessment of Ki67 has poor reproducibility \[[@bib8]\]. More than one factor leads to the poor reproducibility, such as scoring area, scoring method, and variation in the evaluated fields under microscopes \[[@bib9]\]. Although a formal standard method for Ki67 LI assessment have been proposed by the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group \[[@bib7]\], to date there is low reproducibility. In clinical practice, pathologists commonly use visual assessment ('quick-scan rapid Ki67 estimate') or manual counting under the microscope to evaluate Ki67 LI. However, visual assessment lacks interobserver reproducibility \[[@bib9], [@bib10], [@bib11]\]. In manual counting, at least 500--1000 tumor cells have to be counted to achieve acceptable error rates and correct for heterogeneity, a time-consuming and error-prone process \[[@bib7],[@bib12]\]. Digital image analysis (DIA) may be a better candidate for Ki67 assessment, but software does not possess the ability to recognize the region of interest accurately and distinguish every type of breast cancer cell exactly \[[@bib13],[@bib14]\].

Therefore, a well operable and good reproducible Ki67 assessment method is crucial and urgently needed for the precise therapy of breast cancer. In this study, we report a modified Ki67 assessment method, size-set semiautomatic counting (SSSAC) and investigated the interobserver reproducibility among 41 pathologists at 16 hospitals.

2. Materials and methods {#sec2}
========================

2.1. Case selection {#sec2.1}
-------------------

One hundred cases of primary invasive breast cancer paraffin-embedded tissue blocks from surgical specimens were randomly selected from the pathology databases of 920th Hospital of Joint Logistics Support Force of PLA and The Third Affiliated Hospital of Kunming Medical University during the years of 2014 and 2015. All of them are not otherwise specified (NOS) invasive ductal carcinoma,. All the patients received no neoadjuvant chemotherapy before undergoing surgery. All the samples in this study were further consulted by two pathologists according to the standard of World Health Organization \[[@bib15]\].

2.2. Immunohistochemical staining and image acquisition {#sec2.2}
-------------------------------------------------------

Tissue specimens were fixed with 4% neutral buffered formalin and were embedded in paraffin. The paraffin-embedded tumor tissues were cut into 3-μm-thick sections. To minimize the influence caused by the thickness of the tissue sections, all the tumor tissues blocks were cut into 3-μm sections on the same microtome with a standardized speed by one technician. Tissue sections were immunostained with antibody MM1 (Novocastra, Newcastle, U.K.) using the Leica Bond-Max staining robot (Leica Microsystems, Bannockburn, IL, USA) at one laboratory. The 100 qualified slides were digitally scanned into digital slides at × 20 magnification using the Aperiod AT2 digital scanner (Leica Biosystem, Wetzlar, Germany) and then were sent to 41 pathologists at 16 hospitals for Ki67 LI assessment.

2.3. Size-set semiautomatic counting (SSSAC) {#sec2.3}
--------------------------------------------

First, hot spots of Ki67 staining were determined. The nonconformity of scoring areas is a main factor that affects the reproducibility of Ki67 assessment. International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group recommends that, if there are clear hot spots, data from these should be included in the overall score \[[@bib7]\]. Gudlaugsson E et al. showed that Ki67 in the hot spots is of utmost prognostic significance compared with the average and lowest zones \[[@bib11]\]. Accordingly, we defined a hot spot where Ki67 staining is particularly prevalent as the scoring area. In heterogeneous slide, the fields of Ki67-positive tumor cells include high, medium, low staining areas and negligible areas. The high staining area was defined as hot spot \[[@bib16], [@bib17], [@bib18]\]. The digital slides were observed at × 10 magnification to identify hot-spot areas. If the hot spots were distributed in the invasive edge of the tumor, the selection of hot spots should include the invasive edge of the tumor. If the staining of the slides was homogeneous, the scoring area could be any area on the whole slide.

Next, the scoring frames were demarcated. On the area of the hot spot, three 200 × 200-μm square frames were demarcated ([Fig. 1](#fig1){ref-type="fig"}A). Demarcation of the scoring frames in the hot spots were performed as follows: (1) demarcation of three frames successively if the area of the hot spot was sufficiently large; (2) in some slides, the hot spots were insufficient to set three frames---in this circumstance, three frames were demarcated in different hot spots; (3) if the staining was homogeneous, three frames were demarcated randomly; (4) after demarcating three frames in the hot spots, the frames were moved slightly to ensure the Ki67 staining in areas limited by the frames were the highest. Additionally, three frames could not overlap with each other. If the number of cancer cells in the three scoring frames is less than 500, another scoring frame will be demarcated in the hot spot area until the number of cancer cells exceeds 500 ([Fig. 1](#fig1){ref-type="fig"}B).Fig. 1Ki67 assessment of breast cancer. A. Demarcated three scoring frames with the size of 200 × 200 μm on the hot spot. B. More than three scoring frames were demarcated when the cancer cells in three scoring frames were less than 500. C. SSSAC assessment. When clicking on a cancer cell manually the image viewing software covers the cell with a crucial marker and ordinal numbers were presented on the marker automatically. D. SSDIA assessment. The size of 25μm^2^ was set as cut off of nucleus to separate the interstitial cells from breast cancer cells. Ki67 immunostaining of breast cancer cells was set as strong (Red), moderate (Orange), weak (yellow) and negative (Blue).Fig. 1

Finally, the percent of Ki67-positive tumor cells (Ki67 LI) on the Ki67-immunostained digital slides was semiautomatically counted using the digital image viewing software (Aperio Image Scope, Leica, Germany). Only nuclear brown staining is considered Ki67-positive. Staining intensity is not relevant. Tumor cells with blue counterstained nucleus was defined as Ki67-negative cells. Briefly, Ki67-positive tumor cells and negative cells covered by three scoring frames were counted at appreciate magnification by clicking the tumor cells using the mouse button manually. When the mouse button was clicked on target cells, the software covered cells with a crucial marker to avoid counting cells twice, and ordinal numbers were presented on the marker automatically at the same time ([Fig. 1](#fig1){ref-type="fig"}C). When all the Ki67-positive tumor cells were clicked, the total number of Ki67-positive tumor cells was presented in the annotation layer. The Ki67-negative tumor cells were counted by the same method. Finally, the Ki67 LI was defined as \[Ki67-positive cells/(Ki67-positive cells + Ki67-negative cells)\] × 100.

2.4. Size-set visual assessment (SSVA) {#sec2.4}
--------------------------------------

The Ki67 LI of three demarcated scoring frames mentioned above was gained by glancing rapidly by pathologists at × 40 magnification at a digital slide. Brown nuclei rather than blue were scored as positive. The values of Ki67 LI were evaluated at 1% intervals in cases in which the Ki67 LI values were \<10% or \>90%, and the values of Ki67 LI were evaluated at 5% intervals in cases in which the Ki67 LI values were 10%--90%.

2.5. Size-set digital image analysis (SSDIA) {#sec2.5}
--------------------------------------------

The percent values of Ki67-positive cells in the three frames were evaluated automatically using digital image analysis (DIA) software (Aperio Nuclear Algorithm; Leica Biosystems, Germany) referring to manufacturer's manual. Briefly, tumor cell parameters based on the size, smoothing, merging, trimming, roundness, compactness and elongation of the nuclei were developed to distinguish tumor cells from interstitial cells (fibroblasts, fibrocyte, lymphocyte cells, histocytes, endoepitheliocytes). We debugged different tumor cell parameters repeatedly according to the software instructions until almost all of the interstitial cells were separated from cancer cells. ([Fig. 1](#fig1){ref-type="fig"}D). Then, the scoring criteria was modified to define Ki67-negative and Ki67-positive tumor cell nuclei segmented, Ki67 immunostaining of breast cancer cells was set as strong (Red), moderate (Orange), weak (yellow) and negative (Blue), and tumor cells with brown cytoplasm were excluded. Finally, three square frames with a size of 200 × 200 μm were demarcated on the hot spots of each digital slide, and the Ki67 LI of cancer cells demarcated in the three scoring frames were calculated automatically by the Aperio Nuclear Algorithm image analysis software.

2.6. Pathologists {#sec2.6}
-----------------

Total 41 pathologists participated in the assessment of Ki67. Among them, 35 were experienced pathologists who engaged in pathological diagnosis for more than 5 years and 6 inexperienced ones engaged in pathological diagnosis for less than 5 years. 32 came from provincial hospital laboratory and 9 worked in state hospital laboratory.

2.7. Statistical analysis {#sec2.7}
-------------------------

To measure the interobserver reproducibility of the Ki67 LI assessment, the intraclass correlation coefficient (ICC) was estimated with a 95% confidence interval (CI) using two-way mixed models. The ICC has a range of 0--1, with the consensus that the closer distance is to 1, the higher the agreement will be. The ICC demonstrates no universally accepted standard criteria. Hence, based on the similarity to the kappa coefficient, the following criteria were used here to aid interpretation \[[@bib19],[@bib20]\]: \<0.4 indicates "bad correlation"; 0.4--0.69 indicates "moderate correlation"; 0.7--0.79 indicates "substantial correlation"; \>0.80 indicates "almost perfect correlation".

The Bland-Altman plot was used to reveal the difference in the Ki67 LI intuitively between two paired pathologists using the methods of SSVA and SSSAC. If there is high agreement, the differences are expected to be centered about the middle solid line, with a small standard deviation \[[@bib21]\].

The difference between SSSAC and SSDIA values was analyzed using the Wilcoxon signed-rank test.

The ICC and Wilcoxon signed-rank analyses were performed using the software package SPSS 22.0, and Bland-Altman Plot was generated using the software package MedCalc 15.2.2.

3. Results {#sec3}
==========

3.1. Pattern of Ki67 immunostaining {#sec3.1}
-----------------------------------

In 100 cases of breast cancer, 83 cases displayed heterogenous Ki67 immunostaining, that is, there were Ki67 hot spots in these cases ([Fig. 2](#fig2){ref-type="fig"}A), and the remaining 17 cases showed homogeneous distributions of Ki67-positive tumor cells (There were no Ki67 hot spots) ([Fig. 2](#fig2){ref-type="fig"}B). The shapes of the hot spots were varied, such as being round, oval, and irregular. The size, location and distribution of the hot spots are shown in [Table 1](#tbl1){ref-type="table"}. The maximum diameter of the hot spot was 11,740 μm, and the minimum diameter was 50 μm. The diameters of 64% cases were more than 200 μm. The distribution and location of the hot spots were distinct in different cases. The hot spots of 32 cases were distributed centrally ([Fig. 2](#fig2){ref-type="fig"}C), and 51 cases were distributed in a scattered manner ([Fig. 2](#fig2){ref-type="fig"}D). The hot spots were located in the invasive edge of the tumor in 29 cases ([Fig. 2](#fig2){ref-type="fig"}E) and in the interior of the tumor in 40 cases ([Fig. 2](#fig2){ref-type="fig"}F); additionally, the hot spots of the other 14 cases were located both in the invasive edge and interior of the tumor.Fig. 2The pattern of Ki67 immunostaining in breast cancer. A. Heterogenous staining of Ki67. There was a hot spot in the lower-left corner. B. Homogenous staining. C. The hot spot distributed centrally. D. The areas annotated by red circle were scattered hot spots. E. The hot spot in the invasive edge of the tumor. F. The hot spot in the interior of the tumor. A high-resolution version of the image is available as [eSlide:VM00001](eslide:VM00001){#intref0020a}-[VM00006](eslide:VM00006){#intref0020b}.Fig. 2Table 1Size, location and distribution of the hot spots.Table 1Size of hot spot (diameter)nPercentage (%)Distribution of hot spot (n)Location of hot spot (n)centralizedscatteredinvasive edge of the tumorinterior of the tumorinterior and edge of the tumor\<100 μm1316013193100--200 μm1720116494\>200 μm5364312224227

3.2. Size of the scoring frames {#sec3.2}
-------------------------------

We counted the tumor cells covered by different-sized frames and found that each of the 100 × 100-μm, 200 × 200-μm or 300 × 300-μm scoring frames could cover approximately 50, 200 or 600 tumor cells, respectively. Thus, three 200 × 200-μm scoring frames could cover approximately 600 tumor cells (at least 500 tumor cells were required by International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group \[[@bib9]\]). If 100 × 100-μm scoring frames were used, 10 frames must be demarcated to satisfy the requirement of International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group, complicating the Ki67 LI assessment. The 300 × 300-μm scoring frames had a greater possibility to cover non-hot spots around hot spots compared with the 200 × 200-μm scoring frames. Thus, 200 × 200-μm scoring frames were selected in our study.

3.3. Comparison of SSSAC and SSVA/SSDIA {#sec3.3}
---------------------------------------

ICC analysis revealed that SSSAC had higher agreement in Ki67 assessment of breast cancer among inter-pathologists than SSVA. The Ki67 LI obtained by SSSAC had almost perfect concordance among 41 pathologists (ICC, 0.942 \[95% CI: 0.926, 0.957\]) ([Table 2](#tbl2){ref-type="table"}). To further compare the reproducibility of interobserver using SSSAC and SSVA, we randomly selected the Ki67 LI assessment data of 12 pathologists from 41 pathologists, divided into 6 paired groups and compared their Ki67 LI evaluation results with both SSVA and SSSAC using Bland-Altman plots. Six paired Bland-Altman plots intuitively showed that differences were more concentrated about the middle solid line when using SSSAC than using SSVA, demonstrating that SSSAC has higher reproducibility than SSVA ([Fig. 3](#fig3){ref-type="fig"}).Table 2ICC of Ki67 LI in different groups.Table 2GroupsnICC (95% CI)SSVASSSACPathologists All410.942 (0.926, 0.957)0.802 (0.756, 0.846) Experienced pathologists350.805 (0.760, 0.849)0.953 (0.940, 0.965) Inexperienced pathologists60.786 (0.730, 0.837)0.903 (0.873, 0.928)Laboratory Provincial laboratory320.801 (0.755, 0.845)0.946 (0.930, 0.960) The state laboratory90.812 (0.764, 0.856)0.929 (0.907, 0.947)Distribution of Ki67-positive tumor cells homogeneous170.876 (0.791, 0.945)0.967 (0.940, 0.986) centralized hot spot320.745 (0.670, 0.820)0.949 (0.922, 0.970) scattered hot spot510.648 (0.560, 0.742)0.862 (0.812, 0.906)Grade 180.567 (0.352, 0.847)0.955 (0.901, 0.989) 2860.943 (0.862, 0.990)0.947 (0.931, 0.962) 360.761 (0.704, 0.816)0.969 (0.922, 0.995)Fig. 3Bland-Altman Plots analysis of Ki67 LI for 100 cases of breast cancer from 6 paired pathologists. The y-axis represents difference in Ki67 LI assessed by two pathologists. The middle solid line represents the average of the differences from the 2 pathologists. Differences from SSSAC were more concentrated to the middle solid line than that from SSVA.Fig. 3

When the parameters of digital image analysis are set, almost the same results will be produced for the same image. Therefore, DIA could provide precise reproducible analyses. However, it has its own bias and produces inaccurate data. To compare the difference in the Ki67 LI assessed with SSSAC and SSDIA, the mean Ki67 LI of 35 experienced pathologists from 41 pathologists using SSSAC was calculated as the final SSSAC value and then was compared with that of SSDIA data. In 80 cases of breast cancer the Ki67 LI obtained by SSSAC was higher than that obtained by SSDIA. In 17 cases, the Ki67 LI obtained by SSSAC was smaller than that by SSDIA. In three cases, the Ki67 LI obtained by SSSAC was equal to that by SSDIA ([Fig. 4](#fig4){ref-type="fig"}). The maximum difference in the Ki67 LI between SSSAC and SSDIA was 18, and the minimum difference between them was 0. To further demonstrate the difference in the Ki67 value assessed by SSSAC and SSDIA, the data were analyzed by the Wilcoxon signed-rank test, which showed that the Ki67 LI with SSSAC was obviously larger than that with SSDIA (negative ranks (SSDIA \< SSSAC): N = 80, sum of ranks = 4274.50; positive ranks (SSDIA \> SSSAC): N = 17, sum of ranks = 478.50; Z = −6.837, P \< 0.001).Fig. 4Comparison of Ki67 LI in 100 cases of breast cancer between SSSAC and SSDIA assessment (. There were mean Ki67 LI and SD for each case from pathologists in SSSAC line. The Ki67 LI evaluated by SSSAC was larger than that by SSDIA in majority of cases.Fig. 4

3.4. Reproducibility of the different groups {#sec3.4}
--------------------------------------------

According to the number of years that the pathologists were engaged in pathological diagnosis, 41 pathologists were divided into an experienced group (n = 35) and an inexperienced group (n = 6). The ICCs were relatively lower in the inexperienced group than in the experienced group using SSSAC and SSVA. SSSAC showed better reproducibility than SSVA in the two groups ([Table 2](#tbl2){ref-type="table"}). The experienced group showed almost perfect correlation using SSSAC (ICC, 0.953 \[95% CI: 0.940, 0.965\]) and SSVA (ICC, 0.805 \[95% CI: 0.760, 0.849\]). The inexperienced group showed almost perfect correlation using SSSAC (ICC, 0.903 \[95% CI: 0.873, 0.928\]) and a substantial correlation using SSVA (ICC, 0.786 \[95% CI: 0.730, 0.837\]).

To analyze the differences in the Ki67 LI assessment caused by the distribution of Ki67-positive tumor cells, we divided all slides into three groups, the Ki67 homogeneous staining group (n = 16), the centralized Ki67 hot-spot group (n = 33) where hot spots are apparent and concentrated, and the scattered Ki67 hot-spot group (n = 51) where hot spots are noncompact and small. The reproducibility of Ki67 LI assessment in the scattered hot-spot group was obviously lower than that in the homogeneous and centralized hot-spot groups ([Table 2](#tbl2){ref-type="table"}). SSVA presented an almost perfect correlation in the homogeneous group (ICC, 0.876 \[95% CI: 0.791, 0.945\]), a substantial correlation in the centralized hot-spot group (ICC, 0.745 \[95% CI: 0.670, 0.820\]) and a moderate correlation in the scattered hot-spot group (ICC, 0.648 \[95% CI: 0.560, 0.742\]). SSSAC showed a perfect correlation in the homogeneous group (ICC, 0.967 \[95% CI: 0.938, 0.987\]), centralized hot-spot group (ICC, 0.949 \[95% CI: 0.922, 0.970\]), and scattered hot-spot group (ICC, 0.862 \[95% CI: 0.812, 0.906\]).

Furtherly, 41 pathologists were divided into two groups according to the location of the laboratory where they worked, provincial hospital laboratory and state hospital laboratory. The ICCs showed no significant difference between the provincial hospital laboratory and state hospital laboratory whether using SSVA or SSSAC ([Table 2](#tbl2){ref-type="table"}).

To find out whether histological grade had an effect on the reproducibility of Ki67 assessments using these two methods, ICC of grade 1, 2, 3 breast cancer by 41 pathologists were calculated. We found that SSSAC achieved better ICC in grade 1, 2 and 3 breast cancer, indicating that histological grade had no effect on the reproducibility when SSSAC was used. The ICC of SSVA was higher in grade 2 breast cancer, but was lower in grade 1 and grade 3 breast cancer, indicating that the reproducibility of Ki67 assessments would be affected by tumor grade when SSVA was used ([Table 2](#tbl2){ref-type="table"}).

4. Discussion {#sec4}
=============

Ki67 plays an indispensable role in the molecular subtyping of breast cancer and personalized treatment. However, the lack of stability in Ki67 LI assessment is a major obstacle for the development of personalized therapies \[[@bib22]\] and hinders the confident use of Ki67 LI in clinical decisions. The inconsistency of assessment methods is an important reason that leads to poor reproducibility in Ki67 LI assessment. In this study, we recommended a modified Ki67 assessment, size-set semiautomatic counting (SSSAC), which showed satisfactory interobserver reproducibility. SSSAC has some advantages which overcome the factors that cause poor reproducibility of Ki67 assessment, such as defining only hot spots as the scoring area, restricting the size of the scoring area using frames and identifying tumor cells artificially.

SSSAC defines only Ki67 hot spots as the scoring area. Nonconformity of scoring areas is the main factor that affects the reproducibility of Ki67 assessment. Most of the Ki67 staining slides of breast cancer are heterogeneous, including hot spots, cold spots, periphery areas and areas of intermediate proliferation \[[@bib23]\], and Ki67 positive cells in each area are different remarkably. Therefore, the choice of scoring area could cause large differences in Ki67 LI. International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group recommended that, if there are clear hot spots, data from these areas should be included in the overall score \[[@bib7]\]. Gudlaugsson E et al. reported that Ki67 in the hot spots is of utmost prognostic significance compared with the average and lowest zones \[[@bib11]\]. In our study, we divided all the slides into the homogeneous, centralized hot-spot and scattered hot-spot groups. Both SSSAC and SSVA suggested a better correlation in the centralized hot-spot and homogeneous groups compared with the scattered hot-spot group. The reason may be that ensuring the consistency of the scoring area in the centralized hot-spot and homogeneous groups is easier than that in the scattered hot-spot group. Thus, SSSAC only considers hot spots as scoring areas to overcome the negative influence caused by the nonconformity of the scoring areas.

Our SSSAC restricted the size of the scoring area using frames to guarantee similar numbers of counting cells among observers. The size of the scoring field is another factor that causes poor reproducibility of the Ki67 assessment because different sizes of the scoring field cover different cell numbers \[[@bib14]\]. Mikami Y et al. printed photographs of the scoring fields of Ki67 LI to avoid variations in the assessment in various microscopic fields and yielded better concordance than Ki67 LI assessment under a microscope.

The ICC and Bland Altman plot analyses revealed that the reproducibility of SSSAC was better than that of SSVA. SSSAC calculated Ki67 LI by counting each tumor cell using mouse and software in which the counted tumor cells were covered by a crucial marker with the aid of software to avoid repeat counting or missing positive cells that occurred in visual scan and manual counting under a microscope. More than one group demonstrated that counting on real slides affected Ki67 assessment reproducibility. Gudlaugsson E et al. mentioned that the interobserver variation of manual counting was significant \[[@bib11]\]. In Mikami Y 'study the manual counting had a moderate correlation (ICC, 0.66 \[95% CI 0.52--0.78\]) \[[@bib24]\]. Varga, Z et al. found that the standard deviations around the mean values were large when Ki67 LI were obtained by counting Ki67-positive nuclei in real slides \[[@bib18]\].

Additionally, SSSAC-identified tumor cells could avoid the errors observed using DIA. The Wilcoxon signed-rank test showed that Ki67 LI by SSSAC was obviously higher than that by SSDIA. The cause may be that parameter setting by pathologists used in SSDIA to distinguish Ki67-positive and -negative tumor cells cannot recognize every type of breast cancer cell exactly. For example, Ki67-negative lymphocytes and stroma cells may be recognized as Ki67-negative tumor cells, Ki67-positive tumor cells may not be recognized, and 2 contiguous tumor cells may be recognized as 1 tumor cell type.

Although SSSAC has many advantages mentioned above in improving the interobserver reproducibility for Ki67 assessment, there are some weak spots compared with traditional visual assessment. SSSAC is a little bit time-consuming. The method involves slide scanning, hotspot searching, scoring frame demarcating and semi-automatic cell counting, and would take about 8 min for each case. But in order to provide an accurate and reliable Ki67 value LI for precise treatment of breast cancer patients, this time consumption is worthwhile.

In this study, only NOS invasive ductal carcinomas were employed and other histological types of breast cancer such as tubular carcinoma, cribriform carcinoma, papillary carcinoma, and so on, were not involved. The correlation between hot spots and different histological types, as well as the assessment concordance related to different histotypes should be explored in the future.

Breast cancer subtypes based on four marker surrogate immunohistochemistry panel, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67, provide predictive and prognostic information for breast cancer patients \[[@bib25],[@bib26]\]. Meanwhile, genomic testing has been of vital importance in the prognosis and prognostic of breast cancer, such as 21-gene \[[@bib27]\], 70-gene \[[@bib28]\], 50-gene \[[@bib29]\] and so on.

In conclusion, SSSAC possesses the accuracy of manually identifying tumor cells, convenience of semiautomatic counting and satisfactory interobserver reproducibility. We consider SSSAC to be a promising candidate as a standard method for Ki67 LI assessment in breast cancer as well as in other malignancies.
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